Fri, June 17, 2011
Thu, June 16, 2011
Wed, June 15, 2011
Tue, June 14, 2011
[ Tue, Jun 14th 2011 ]: Market Wire
Bond Labs Reports May Results
Mon, June 13, 2011
Fri, June 10, 2011
Thu, June 9, 2011
Wed, June 8, 2011
Tue, June 7, 2011
Mon, June 6, 2011
Sat, June 4, 2011
Fri, June 3, 2011
Thu, June 2, 2011
Wed, June 1, 2011
Tue, May 31, 2011
Mon, May 30, 2011
Fri, May 27, 2011
Thu, May 26, 2011
Wed, May 25, 2011
Tue, May 24, 2011
Mon, May 23, 2011
Sun, May 22, 2011
Fri, May 20, 2011
Thu, May 19, 2011
Wed, May 18, 2011

ARIAD to Present at the Jefferies 2011 Global Healthcare Conference


//health-fitness.news-articles.net/content/2011/ .. jefferies-2011-global-healthcare-conference.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--[ ARIAD Pharmaceuticals, Inc. ] (NASDAQ: ARIA) today announced that it will present at the Jefferies 2011 Global Healthcare Conference being held at the Grand Hyatt Hotel in New York City. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Companya™s strong oncology pipeline on Wednesday, June 8 at 9:30 a.m. (ET).

The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at [ http://www.ariad.com/investor ]. A replay of the presentation will also be available and archived on the site for 90 days.

About ARIAD

ARIADa™s vision is to transform the lives of cancer patients with breakthrough medicines. The Companya™s mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need - aggressive cancers where current therapies are inadequate. ARIADa™s product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck that has successfully completed a Phase 3 clinical trial in patients with soft-tissue and bone sarcomas and is being studied in multiple cancer indications. ARIADa™s second internally discovered product candidate, ponatinib, is an investigational pan-BCR-ABL inhibitor in a pivotal Phase 2 clinical trial in patients with chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. For additional information, please visit [ http://www.ariad.com ].


Publication Contributing Sources

Publication Sponsors
[ Last Sunday ] - Oceanside Rental Gear